The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Eftrenonacog Alfa Market Research Report 2025
Synopsis
Eftrenonacog alfa is a long-acting recombinant fusion protein used in the treatment of hemophilia B. It is comprised of a single molecule of human factor IX (FIX) covalently linked to the constant region (Fc) domain of human IgG1 via recombinant DNA technology in a human embryonic kidney cell line (HEK293H) 1. The presence of the Fc domain extends the terminal half-life which confers clinical benefits of prolonged therapeutic efficacy, less frequent intravenous injections for patient convenience and improved adherence to prophylaxis.
The global Eftrenonacog Alfa market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Eftrenonacog Alfa, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Eftrenonacog Alfa.
Report Scope
The Eftrenonacog Alfa market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Eftrenonacog Alfa market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Eftrenonacog Alfa manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Vetter Pharma-Fertigung GmbH & Co.KG
Sanofi Aventis
Bioverativ Therapeutics Inc.
Biogen Inc
SWEDISH ORPHAN BIOVITRUM AB
Segment by Type
250IU
500IU
1000IU
2000IU
Segment by Application
Hemophilia
Surgical Bleeding
Long-term Bleeding Prevention
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Eftrenonacog Alfa manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Eftrenonacog Alfa in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Eftrenonacog alfa is a long-acting recombinant fusion protein used in the treatment of hemophilia B. It is comprised of a single molecule of human factor IX (FIX) covalently linked to the constant region (Fc) domain of human IgG1 via recombinant DNA technology in a human embryonic kidney cell line (HEK293H) 1. The presence of the Fc domain extends the terminal half-life which confers clinical benefits of prolonged therapeutic efficacy, less frequent intravenous injections for patient convenience and improved adherence to prophylaxis.
The global Eftrenonacog Alfa market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Eftrenonacog Alfa, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Eftrenonacog Alfa.
Report Scope
The Eftrenonacog Alfa market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Eftrenonacog Alfa market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Eftrenonacog Alfa manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Vetter Pharma-Fertigung GmbH & Co.KG
Sanofi Aventis
Bioverativ Therapeutics Inc.
Biogen Inc
SWEDISH ORPHAN BIOVITRUM AB
Segment by Type
250IU
500IU
1000IU
2000IU
Segment by Application
Hemophilia
Surgical Bleeding
Long-term Bleeding Prevention
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Eftrenonacog Alfa manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Eftrenonacog Alfa in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Eftrenonacog Alfa Market Overview
1.1 Product Overview and Scope of Eftrenonacog Alfa
1.2 Eftrenonacog Alfa Segment by Type
1.2.1 Global Eftrenonacog Alfa Market Value Comparison by Type (2024-2030)
1.2.2 250IU
1.2.3 500IU
1.2.4 1000IU
1.2.5 2000IU
1.3 Eftrenonacog Alfa Segment by Application
1.3.1 Global Eftrenonacog Alfa Market Value by Application: (2024-2030)
1.3.2 Hemophilia
1.3.3 Surgical Bleeding
1.3.4 Long-term Bleeding Prevention
1.4 Global Eftrenonacog Alfa Market Size Estimates and Forecasts
1.4.1 Global Eftrenonacog Alfa Revenue 2019-2030
1.4.2 Global Eftrenonacog Alfa Sales 2019-2030
1.4.3 Global Eftrenonacog Alfa Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Eftrenonacog Alfa Market Competition by Manufacturers
2.1 Global Eftrenonacog Alfa Sales Market Share by Manufacturers (2019-2024)
2.2 Global Eftrenonacog Alfa Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Eftrenonacog Alfa Average Price by Manufacturers (2019-2024)
2.4 Global Eftrenonacog Alfa Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Eftrenonacog Alfa, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Eftrenonacog Alfa, Product Type & Application
2.7 Eftrenonacog Alfa Market Competitive Situation and Trends
2.7.1 Eftrenonacog Alfa Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Eftrenonacog Alfa Players Market Share by Revenue
2.7.3 Global Eftrenonacog Alfa Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Eftrenonacog Alfa Retrospective Market Scenario by Region
3.1 Global Eftrenonacog Alfa Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Eftrenonacog Alfa Global Eftrenonacog Alfa Sales by Region: 2019-2030
3.2.1 Global Eftrenonacog Alfa Sales by Region: 2019-2024
3.2.2 Global Eftrenonacog Alfa Sales by Region: 2025-2030
3.3 Global Eftrenonacog Alfa Global Eftrenonacog Alfa Revenue by Region: 2019-2030
3.3.1 Global Eftrenonacog Alfa Revenue by Region: 2019-2024
3.3.2 Global Eftrenonacog Alfa Revenue by Region: 2025-2030
3.4 North America Eftrenonacog Alfa Market Facts & Figures by Country
3.4.1 North America Eftrenonacog Alfa Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Eftrenonacog Alfa Sales by Country (2019-2030)
3.4.3 North America Eftrenonacog Alfa Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Eftrenonacog Alfa Market Facts & Figures by Country
3.5.1 Europe Eftrenonacog Alfa Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Eftrenonacog Alfa Sales by Country (2019-2030)
3.5.3 Europe Eftrenonacog Alfa Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Eftrenonacog Alfa Market Facts & Figures by Country
3.6.1 Asia Pacific Eftrenonacog Alfa Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Eftrenonacog Alfa Sales by Country (2019-2030)
3.6.3 Asia Pacific Eftrenonacog Alfa Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Eftrenonacog Alfa Market Facts & Figures by Country
3.7.1 Latin America Eftrenonacog Alfa Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Eftrenonacog Alfa Sales by Country (2019-2030)
3.7.3 Latin America Eftrenonacog Alfa Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Eftrenonacog Alfa Market Facts & Figures by Country
3.8.1 Middle East and Africa Eftrenonacog Alfa Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Eftrenonacog Alfa Sales by Country (2019-2030)
3.8.3 Middle East and Africa Eftrenonacog Alfa Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Eftrenonacog Alfa Sales by Type (2019-2030)
4.1.1 Global Eftrenonacog Alfa Sales by Type (2019-2024)
4.1.2 Global Eftrenonacog Alfa Sales by Type (2025-2030)
4.1.3 Global Eftrenonacog Alfa Sales Market Share by Type (2019-2030)
4.2 Global Eftrenonacog Alfa Revenue by Type (2019-2030)
4.2.1 Global Eftrenonacog Alfa Revenue by Type (2019-2024)
4.2.2 Global Eftrenonacog Alfa Revenue by Type (2025-2030)
4.2.3 Global Eftrenonacog Alfa Revenue Market Share by Type (2019-2030)
4.3 Global Eftrenonacog Alfa Price by Type (2019-2030)
5 Segment by Application
5.1 Global Eftrenonacog Alfa Sales by Application (2019-2030)
5.1.1 Global Eftrenonacog Alfa Sales by Application (2019-2024)
5.1.2 Global Eftrenonacog Alfa Sales by Application (2025-2030)
5.1.3 Global Eftrenonacog Alfa Sales Market Share by Application (2019-2030)
5.2 Global Eftrenonacog Alfa Revenue by Application (2019-2030)
5.2.1 Global Eftrenonacog Alfa Revenue by Application (2019-2024)
5.2.2 Global Eftrenonacog Alfa Revenue by Application (2025-2030)
5.2.3 Global Eftrenonacog Alfa Revenue Market Share by Application (2019-2030)
5.3 Global Eftrenonacog Alfa Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Vetter Pharma-Fertigung GmbH & Co.KG
6.1.1 Vetter Pharma-Fertigung GmbH & Co.KG Corporation Information
6.1.2 Vetter Pharma-Fertigung GmbH & Co.KG Description and Business Overview
6.1.3 Vetter Pharma-Fertigung GmbH & Co.KG Eftrenonacog Alfa Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Vetter Pharma-Fertigung GmbH & Co.KG Eftrenonacog Alfa Product Portfolio
6.1.5 Vetter Pharma-Fertigung GmbH & Co.KG Recent Developments/Updates
6.2 Sanofi Aventis
6.2.1 Sanofi Aventis Corporation Information
6.2.2 Sanofi Aventis Description and Business Overview
6.2.3 Sanofi Aventis Eftrenonacog Alfa Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Sanofi Aventis Eftrenonacog Alfa Product Portfolio
6.2.5 Sanofi Aventis Recent Developments/Updates
6.3 Bioverativ Therapeutics Inc.
6.3.1 Bioverativ Therapeutics Inc. Corporation Information
6.3.2 Bioverativ Therapeutics Inc. Description and Business Overview
6.3.3 Bioverativ Therapeutics Inc. Eftrenonacog Alfa Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Bioverativ Therapeutics Inc. Eftrenonacog Alfa Product Portfolio
6.3.5 Bioverativ Therapeutics Inc. Recent Developments/Updates
6.4 Biogen Inc
6.4.1 Biogen Inc Corporation Information
6.4.2 Biogen Inc Description and Business Overview
6.4.3 Biogen Inc Eftrenonacog Alfa Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Biogen Inc Eftrenonacog Alfa Product Portfolio
6.4.5 Biogen Inc Recent Developments/Updates
6.5 SWEDISH ORPHAN BIOVITRUM AB
6.5.1 SWEDISH ORPHAN BIOVITRUM AB Corporation Information
6.5.2 SWEDISH ORPHAN BIOVITRUM AB Description and Business Overview
6.5.3 SWEDISH ORPHAN BIOVITRUM AB Eftrenonacog Alfa Sales, Revenue and Gross Margin (2019-2024)
6.5.4 SWEDISH ORPHAN BIOVITRUM AB Eftrenonacog Alfa Product Portfolio
6.5.5 SWEDISH ORPHAN BIOVITRUM AB Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Eftrenonacog Alfa Industry Chain Analysis
7.2 Eftrenonacog Alfa Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Eftrenonacog Alfa Production Mode & Process
7.4 Eftrenonacog Alfa Sales and Marketing
7.4.1 Eftrenonacog Alfa Sales Channels
7.4.2 Eftrenonacog Alfa Distributors
7.5 Eftrenonacog Alfa Customers
8 Eftrenonacog Alfa Market Dynamics
8.1 Eftrenonacog Alfa Industry Trends
8.2 Eftrenonacog Alfa Market Drivers
8.3 Eftrenonacog Alfa Market Challenges
8.4 Eftrenonacog Alfa Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Eftrenonacog Alfa Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Eftrenonacog Alfa Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Eftrenonacog Alfa Market Competitive Situation by Manufacturers in 2023
Table 4. Global Eftrenonacog Alfa Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Eftrenonacog Alfa Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Eftrenonacog Alfa Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Eftrenonacog Alfa Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Eftrenonacog Alfa Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Eftrenonacog Alfa, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Eftrenonacog Alfa, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Eftrenonacog Alfa, Product Type & Application
Table 12. Global Key Manufacturers of Eftrenonacog Alfa, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Eftrenonacog Alfa by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Eftrenonacog Alfa as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Eftrenonacog Alfa Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Eftrenonacog Alfa Sales by Region (2019-2024) & (K Units)
Table 18. Global Eftrenonacog Alfa Sales Market Share by Region (2019-2024)
Table 19. Global Eftrenonacog Alfa Sales by Region (2025-2030) & (K Units)
Table 20. Global Eftrenonacog Alfa Sales Market Share by Region (2025-2030)
Table 21. Global Eftrenonacog Alfa Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Eftrenonacog Alfa Revenue Market Share by Region (2019-2024)
Table 23. Global Eftrenonacog Alfa Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Eftrenonacog Alfa Revenue Market Share by Region (2025-2030)
Table 25. North America Eftrenonacog Alfa Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Eftrenonacog Alfa Sales by Country (2019-2024) & (K Units)
Table 27. North America Eftrenonacog Alfa Sales by Country (2025-2030) & (K Units)
Table 28. North America Eftrenonacog Alfa Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Eftrenonacog Alfa Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Eftrenonacog Alfa Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Eftrenonacog Alfa Sales by Country (2019-2024) & (K Units)
Table 32. Europe Eftrenonacog Alfa Sales by Country (2025-2030) & (K Units)
Table 33. Europe Eftrenonacog Alfa Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Eftrenonacog Alfa Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Eftrenonacog Alfa Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Eftrenonacog Alfa Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Eftrenonacog Alfa Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Eftrenonacog Alfa Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Eftrenonacog Alfa Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Eftrenonacog Alfa Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Eftrenonacog Alfa Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Eftrenonacog Alfa Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Eftrenonacog Alfa Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Eftrenonacog Alfa Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Eftrenonacog Alfa Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Eftrenonacog Alfa Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Eftrenonacog Alfa Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Eftrenonacog Alfa Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Eftrenonacog Alfa Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Eftrenonacog Alfa Sales (K Units) by Type (2019-2024)
Table 51. Global Eftrenonacog Alfa Sales (K Units) by Type (2025-2030)
Table 52. Global Eftrenonacog Alfa Sales Market Share by Type (2019-2024)
Table 53. Global Eftrenonacog Alfa Sales Market Share by Type (2025-2030)
Table 54. Global Eftrenonacog Alfa Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Eftrenonacog Alfa Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Eftrenonacog Alfa Revenue Market Share by Type (2019-2024)
Table 57. Global Eftrenonacog Alfa Revenue Market Share by Type (2025-2030)
Table 58. Global Eftrenonacog Alfa Price (US$/Unit) by Type (2019-2024)
Table 59. Global Eftrenonacog Alfa Price (US$/Unit) by Type (2025-2030)
Table 60. Global Eftrenonacog Alfa Sales (K Units) by Application (2019-2024)
Table 61. Global Eftrenonacog Alfa Sales (K Units) by Application (2025-2030)
Table 62. Global Eftrenonacog Alfa Sales Market Share by Application (2019-2024)
Table 63. Global Eftrenonacog Alfa Sales Market Share by Application (2025-2030)
Table 64. Global Eftrenonacog Alfa Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Eftrenonacog Alfa Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Eftrenonacog Alfa Revenue Market Share by Application (2019-2024)
Table 67. Global Eftrenonacog Alfa Revenue Market Share by Application (2025-2030)
Table 68. Global Eftrenonacog Alfa Price (US$/Unit) by Application (2019-2024)
Table 69. Global Eftrenonacog Alfa Price (US$/Unit) by Application (2025-2030)
Table 70. Vetter Pharma-Fertigung GmbH & Co.KG Corporation Information
Table 71. Vetter Pharma-Fertigung GmbH & Co.KG Description and Business Overview
Table 72. Vetter Pharma-Fertigung GmbH & Co.KG Eftrenonacog Alfa Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Vetter Pharma-Fertigung GmbH & Co.KG Eftrenonacog Alfa Product
Table 74. Vetter Pharma-Fertigung GmbH & Co.KG Recent Developments/Updates
Table 75. Sanofi Aventis Corporation Information
Table 76. Sanofi Aventis Description and Business Overview
Table 77. Sanofi Aventis Eftrenonacog Alfa Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Sanofi Aventis Eftrenonacog Alfa Product
Table 79. Sanofi Aventis Recent Developments/Updates
Table 80. Bioverativ Therapeutics Inc. Corporation Information
Table 81. Bioverativ Therapeutics Inc. Description and Business Overview
Table 82. Bioverativ Therapeutics Inc. Eftrenonacog Alfa Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Bioverativ Therapeutics Inc. Eftrenonacog Alfa Product
Table 84. Bioverativ Therapeutics Inc. Recent Developments/Updates
Table 85. Biogen Inc Corporation Information
Table 86. Biogen Inc Description and Business Overview
Table 87. Biogen Inc Eftrenonacog Alfa Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Biogen Inc Eftrenonacog Alfa Product
Table 89. Biogen Inc Recent Developments/Updates
Table 90. SWEDISH ORPHAN BIOVITRUM AB Corporation Information
Table 91. SWEDISH ORPHAN BIOVITRUM AB Description and Business Overview
Table 92. SWEDISH ORPHAN BIOVITRUM AB Eftrenonacog Alfa Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. SWEDISH ORPHAN BIOVITRUM AB Eftrenonacog Alfa Product
Table 94. SWEDISH ORPHAN BIOVITRUM AB Recent Developments/Updates
Table 95. Key Raw Materials Lists
Table 96. Raw Materials Key Suppliers Lists
Table 97. Eftrenonacog Alfa Distributors List
Table 98. Eftrenonacog Alfa Customers List
Table 99. Eftrenonacog Alfa Market Trends
Table 100. Eftrenonacog Alfa Market Drivers
Table 101. Eftrenonacog Alfa Market Challenges
Table 102. Eftrenonacog Alfa Market Restraints
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Eftrenonacog Alfa
Figure 2. Global Eftrenonacog Alfa Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Eftrenonacog Alfa Market Share by Type in 2023 & 2030
Figure 4. 250IU Product Picture
Figure 5. 500IU Product Picture
Figure 6. 1000IU Product Picture
Figure 7. 2000IU Product Picture
Figure 8. Global Eftrenonacog Alfa Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Eftrenonacog Alfa Market Share by Application in 2023 & 2030
Figure 10. Hemophilia
Figure 11. Surgical Bleeding
Figure 12. Long-term Bleeding Prevention
Figure 13. Global Eftrenonacog Alfa Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Eftrenonacog Alfa Market Size (2019-2030) & (US$ Million)
Figure 15. Global Eftrenonacog Alfa Sales (2019-2030) & (K Units)
Figure 16. Global Eftrenonacog Alfa Average Price (US$/Unit) & (2019-2030)
Figure 17. Eftrenonacog Alfa Report Years Considered
Figure 18. Eftrenonacog Alfa Sales Share by Manufacturers in 2023
Figure 19. Global Eftrenonacog Alfa Revenue Share by Manufacturers in 2023
Figure 20. The Global 5 and 10 Largest Eftrenonacog Alfa Players: Market Share by Revenue in 2023
Figure 21. Eftrenonacog Alfa Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 22. Global Eftrenonacog Alfa Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 23. North America Eftrenonacog Alfa Sales Market Share by Country (2019-2030)
Figure 24. North America Eftrenonacog Alfa Revenue Market Share by Country (2019-2030)
Figure 25. United States Eftrenonacog Alfa Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Canada Eftrenonacog Alfa Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Europe Eftrenonacog Alfa Sales Market Share by Country (2019-2030)
Figure 28. Europe Eftrenonacog Alfa Revenue Market Share by Country (2019-2030)
Figure 29. Germany Eftrenonacog Alfa Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. France Eftrenonacog Alfa Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. U.K. Eftrenonacog Alfa Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Italy Eftrenonacog Alfa Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Russia Eftrenonacog Alfa Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Asia Pacific Eftrenonacog Alfa Sales Market Share by Region (2019-2030)
Figure 35. Asia Pacific Eftrenonacog Alfa Revenue Market Share by Region (2019-2030)
Figure 36. China Eftrenonacog Alfa Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Japan Eftrenonacog Alfa Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. South Korea Eftrenonacog Alfa Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. India Eftrenonacog Alfa Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Australia Eftrenonacog Alfa Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. China Taiwan Eftrenonacog Alfa Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Southeast Asia Eftrenonacog Alfa Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Latin America Eftrenonacog Alfa Sales Market Share by Country (2019-2030)
Figure 44. Latin America Eftrenonacog Alfa Revenue Market Share by Country (2019-2030)
Figure 45. Mexico Eftrenonacog Alfa Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Brazil Eftrenonacog Alfa Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Argentina Eftrenonacog Alfa Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Eftrenonacog Alfa Sales Market Share by Country (2019-2030)
Figure 49. Middle East & Africa Eftrenonacog Alfa Revenue Market Share by Country (2019-2030)
Figure 50. Turkey Eftrenonacog Alfa Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Eftrenonacog Alfa Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. UAE Eftrenonacog Alfa Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Global Sales Market Share of Eftrenonacog Alfa by Type (2019-2030)
Figure 54. Global Revenue Market Share of Eftrenonacog Alfa by Type (2019-2030)
Figure 55. Global Eftrenonacog Alfa Price (US$/Unit) by Type (2019-2030)
Figure 56. Global Sales Market Share of Eftrenonacog Alfa by Application (2019-2030)
Figure 57. Global Revenue Market Share of Eftrenonacog Alfa by Application (2019-2030)
Figure 58. Global Eftrenonacog Alfa Price (US$/Unit) by Application (2019-2030)
Figure 59. Eftrenonacog Alfa Value Chain
Figure 60. Eftrenonacog Alfa Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
